Tim Smith

These new data, presented at EADV, highlight remibrutinib’s impact on specific IgG autoantibody levels in individuals with chronic spontaneous urticaria (CSU).

This approval by the FDA of ruxolitinib cream for children aged 2-11 years atopic dermatitis follows recent positive clinical trial findings on the treatment.

This analysis highlights the safety and efficacy of JAK3/TEC inhibition in cicatricial alopecias, presented at EADV.

These late-breaking data at EADV highlight predictive factors for early super response to treatment with bimekizumab for psoriasis.

These HS-OBTAIN phase 2a trial data highlight the impacts of treatment with brivekimig on patients naïve to biologics with moderate-to-severe HS.

This study highlights improvements with izokibep for HS, sustained or improved across disease measures through to Week 16.

These 24-week, interim data from the phase STOP-HS study highlight the impacts of povorcitinib on patients with hidradenitis suppurativa (HS).

Patients with atopic dermatitis treated with camoteskimab saw significant reductions in their mean EASI score at Week 16 compared to placebo.

In this analysis, the degree to which each dermatological condition impacts biological aging was highlighted using epigenetic clocks.

This letter explores off-label dosing adjustments for patients with psoriasis using the IL-17A inhibitors secukinumab and ixekizumab.

This review highlights several evidence-based approaches to promoting skin longevity and preventing signs of aging.

In this study, investigators assessed how the prescription patterns of biologics, non-biologic systemic agents, and phototherapy are altered after cardiovascular events.

A new position paper established an evidence-based definition for systemic corticosteroid (SCS) duration in individuals with atopic dermatitis.

These data indicate that greater maternal dietary diversity during pregnancy may be linked with a diminished risk of atopic dermatitis during early childhood.

This study compared a recent risk prediction tool for invasive melanoma and its performance compared to existing prediction tools.

These data underscore the value of individualized cancer risk evaluations when selecting treatment strategies for psoriasis.

Preliminary topline results have been released from the ASCEND study on rocatinlimab in adults and adolescents with atopic dermatitis.

Investigators systematically reviewed NB-UVB treatment responses for psoriasis in patients with skin of color.

This announcement highlights delgocitinib cream availability for the treatment of US adults living with moderate-to-severe chronic hand eczema, or CHE.

In this observational analysis, investigators highlight the potential causal link identified between NHHR and psoriasis development.

Investigators explored the characteristics of pediatric-onset hidradenitis suppurativa, emphasizing the need for earlier detection to expedite diagnosis.

NB-UVB phototherapy was highlighted in this study, with positive findings suggesting the treatment is an effective oral cyclosporine alternative.

Investigators highlighted the cardiovascular safety of systemic treatments for psoriasis such as methotrexate and tumor necrosis factor inhibitors.

Amlitelimab met its primary and key secondary endpoints in the COAST 1 phase 3 study of adults and adolescents with atopic dermatitis.

This analysis highlights bimekizumab’s impact on psoriasis clearance compared to ustekinumab, secukinumab, and adalimumab.

This announcement regarding the new sNDA for roflumilast cream in pediatric patients with psoriasis follows positive findings from the MUSE study.

This study highlighted VTE risk factors in a cohort of patients with alopecia areata who were eligible for baricitinib treatment.

In this analysis, investigators looked at the importance of skin clearance and daily time trade off (dTTO) among adult patients living with chronic hand eczema (CHE).